Characterization of New ATM Deletion Associated with Hereditary Breast Cancer
Open Access
- 21 January 2021
- Vol. 12 (2), 136
- https://doi.org/10.3390/genes12020136
Abstract
Next-generation sequencing (NGS)-based cancer risk screening with multigene panels has become the most successful method for programming cancer prevention strategies. ATM germ-line heterozygosity has been described to increase tumor susceptibility. In particular, families carrying heterozygous germ-line variants of ATM gene have a 5- to 9-fold risk of developing breast cancer. Recent studies identified ATM as the second most mutated gene after CHEK2 in BRCA-negative patients. Nowadays, more than 170 missense variants and several truncating mutations have been identified in ATM gene. Here, we present the molecular characterization of a new ATM deletion, identified thanks to the CNV algorithm implemented in the NGS analysis pipeline. An automated workflow implementing the SOPHiA Genetics’ Hereditary Cancer Solution (HCS) protocol was used to generate NGS libraries that were sequenced on Illumina MiSeq Platform. NGS data analysis allowed us to identify a new inactivating deletion of exons 19–27 of ATM gene. The deletion was characterized both at the DNA and RNA level.This publication has 14 references indexed in Scilit:
- Breast cancerNature Reviews Disease Primers, 2019
- Multi-Gene Panel Testing of 23,179 Individuals for Hereditary Cancer Risk Identifies Pathogenic Variant Carriers Missed by Current Genetic Testing GuidelinesThe Journal of Molecular Diagnostics, 2019
- Morphology and genomic hallmarks of breast tumours developed by ATM deleterious variant carriersBreast Cancer Research, 2018
- Ataxia–Telangiectasia Gene (ATM) Mutation Heterozygosity in Breast Cancer: A Narrative ReviewCurrent Oncology, 2018
- Multi-gene panel testing for hereditary cancer predisposition in unsolved high-risk breast and ovarian cancer patientsBreast Cancer Research and Treatment, 2017
- Updates on breast cancer genetics: Clinical implications of detecting syndromes of inherited increased susceptibility to breast cancerSeminars in Oncology, 2016
- ATM Mutations in Cancer: Therapeutic ImplicationsMolecular Cancer Therapeutics, 2016
- Pathogenic and likely pathogenic variant prevalence among the first 10,000 patients referred for next-generation cancer panel testingGenetics in Medicine, 2016
- Penetrance of ATM Gene Mutations in Breast Cancer: A Meta‐Analysis of Different Measures of RiskGenetic Epidemiology, 2016
- ZFP36L1 Negatively Regulates Erythroid Differentiation of CD34+ Hematopoietic Stem Cells by Interfering with the Stat5b PathwayMolecular Biology of the Cell, 2010